Xue Wu - Shandong Weigao Chief Officer
| SHWGY Stock | USD 2.27 0.04 1.79% |
Executive
Mr. Wu Xue Feng is Chief Financial Officer of the Company. He has over 15 years of extensive experience in the accounting and finance sectors. Mr. Wu joined the finance department of the Company in July 2001. He was the manager of the finance department of the production unit of the Company since January 2005 and responsible for production cost auditing and control. He was the manager of the finance department of the sales unit of the Company since June 2009 and responsible for auditing and management of sales business. He worked as the manager of the risk management department of Weigao Holding Company Limited, the controlling shareholder of the Company, since July 2012. He was appointed as the financial controller of the distribution business department of Weigao Holding Company Limited since October 2013 since 2017.
| Age | 45 |
| Tenure | 7 years |
| Phone | 86 63 1562 1999 |
| Web | https://www.weigaogroup.com |
Shandong Weigao Management Efficiency
The company has return on total asset (ROA) of 0.0604 % which means that it generated a profit of $0.0604 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1276 %, meaning that it generated $0.1276 on every $100 dollars invested by stockholders. Shandong Weigao's management efficiency ratios could be used to measure how well Shandong Weigao manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Wolfgang Becker | Straumann Holding AG | 57 | |
| Laura Piccinini | AngioDynamics | 55 | |
| Kaushik Ghoshal | ResMed Inc | 56 | |
| Michael Fliss | ResMed Inc | N/A | |
| Mark Fox | Utah Medical Products | N/A | |
| Dianne Heiler | Repligen | N/A | |
| Kimberly Cornwell | Repligen | N/A | |
| Judy CFA | Nephros | 59 | |
| MS MBA | Nephros | 50 | |
| Paul Sumilas | Envista Holdings Corp | N/A | |
| Michael Rider | ResMed Inc | 66 | |
| Nathaniel Esq | STAAR Surgical | 50 | |
| Clay Fradd | ICU Medical | N/A | |
| Brian Lloyd | Merit Medical Systems | 63 | |
| Brianne McGuire | Nephros | N/A | |
| Christine Gebski | Repligen | 56 | |
| Jon Snodgres | Repligen | 58 | |
| Filippo Impieri | Envista Holdings Corp | N/A | |
| Judy Mazzini | Nephros | N/A | |
| Saleem Cheeks | AngioDynamics | N/A | |
| Mark Butler | Merit Medical Systems | N/A | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0604 |
Shandong Weigao Group Leadership Team
Elected by the shareholders, the Shandong Weigao's board of directors comprises two types of representatives: Shandong Weigao inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shandong. The board's role is to monitor Shandong Weigao's management team and ensure that shareholders' interests are well served. Shandong Weigao's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shandong Weigao's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Junqiang Lu, Ex Director | ||
| Shili Ni, Ex Director | ||
| Miu Wong, Company Secretary | ||
| Hong Ju, Vice-General Manager of the Production and Supply Chain | ||
| Rinan Cong, CEO Director | ||
| Xue Wu, Chief Officer | ||
| Jing Long, Vice-General Manager of Marketing Management |
Shandong Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Shandong Weigao a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0604 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 6.75 B | |||
| Shares Outstanding | 1.13 B | |||
| Price To Earning | 19.07 X | |||
| Price To Book | 2.18 X | |||
| Price To Sales | 0.51 X | |||
| Revenue | 13.15 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Shandong Pink Sheet Analysis
When running Shandong Weigao's price analysis, check to measure Shandong Weigao's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shandong Weigao is operating at the current time. Most of Shandong Weigao's value examination focuses on studying past and present price action to predict the probability of Shandong Weigao's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shandong Weigao's price. Additionally, you may evaluate how the addition of Shandong Weigao to your portfolios can decrease your overall portfolio volatility.